enokizumab

Home
Ligands
enokizumab

GtoPdb Ligand ID: 8934

Synonyms: 7F3com-2H2 | MEDI-528 | MEDI528

Comment: Enokizumab is a humanized monoclonal antibody targeting interleukin 9 (IL-9), being investigated for its immunomodulatory potential.
Peptide sequences for this antibody are available from its IMGT/mAb-DB record.
BLAST peptide searches using the variable regions of the heavy and light chains of the antibody reveal exact matches with sequences submitted with patent US7354584 [5], which correspond to antibody construct 7F3com-2H2 therein..

No information available.

No information available.

Summary of Clinical Use
Enokizumab has been evaluated in Phase 2 clinical trials as a potential anti-asthmatic therapy [2,4]. Click here to link to ClinicalTrials.gov's full listing of Phase 2 enokizumab (research coded MEDI528 or MEDI0528) trials.

Summary of Clinical Use

Enokizumab has been evaluated in Phase 2 clinical trials as a potential anti-asthmatic therapy [2,4]. Click here to link to ClinicalTrials.gov's full listing of Phase 2 enokizumab (research coded MEDI528 or MEDI0528) trials.

Mechanism Of Action and Pharmacodynamic Effects
Preclinical studies suggest that IL-9 is a potential key mediator in the development and maintenance of airway inflammation in asthma. Anti-IL-9 therapy is considered to address the unmet need for controlling disease in patients unresponsive to current treatment strategies. The role of the IL-9-mast cell axis in asthma is reviewed in [3].

Mechanism Of Action and Pharmacodynamic Effects

Preclinical studies suggest that IL-9 is a potential key mediator in the development and maintenance of airway inflammation in asthma. Anti-IL-9 therapy is considered to address the unmet need for controlling disease in patients unresponsive to current treatment strategies. The role of the IL-9-mast cell axis in asthma is reviewed in [3].